Business The never ending Biogen Alzheimer’s drug saga delivers yet another twist Published 3 years ago on 9 July 2021 By Terry Power The drama of the FDA’s approval of Biogen’s Aduhelm is far from over. But what happens next? Read More Related Topics:aducanumabaduhelm labeladuhelm prescriptionAlzheimersbiogenbiogen aduhelm labelcoronavirusCOVIDCOVID-19deliversdrugFDAfda aduhelm labelfda biogenfda biogen approvalfood and drug administrationsagatwist